10/561414 MP12 Rec'd PCT/PTO 19 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Borthwick, et al.

International App. No.:

PCT/EP2004/006603

Group Art Unit:

International Filing Date:

June 17, 2004

Examiner:

FOR:

PYRROLIDINE - 2- ONES AS FACTOR XA INHIBITORS

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[] Co [X] A Po Ro	ppies of the references are enclosed pies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) copy of the International Search Report which issued on International Application No. CT/EP2004/006603 is submitted herewith. All of the publications cited in the International Search export are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied the U.S. Patent Office by the International Bureau.
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, nichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

10/561414 PAP12 Rec'd PCT/PTO 19 DEC 2005

C.	The Information Disclosure Statement transmitted herewith is being filed after a final action 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment issue fee. Also enclosed is a copy of the International Search Report which Issued on Internation No.					
	In acco	ordance with the requirements of 37 CFR 1.97(d):				
]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.				
	[]	Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).				
	[]	The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.				
[X	-	charge any required fees to Deposit Account No.07-1392.				

Respectfully Submitted,

Amy H. Fix

Attorney for Appliant Registration No. 42,616

Date: 16 Dec. 2005

GlaxoSmithKline

Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8911 Facsimile: (919) 483-7988

AP12 Rec'd PCT/PTO 19 DFC 2005 Page 1 of 1

				87 til	12 1100 01 0 1/1			
FORM PT					ATTORNEY DOCKET INTERNATIONAL			IONAL
INFORMA	ATION	N DISCLOSURE	STATEMEN	Γ	NO.	APP. NO.		
					PB60627USW		PCT/EP2004/006603	
					APPLICANT			
					Borthwick et al.			
				INTERNATIONAL FILING DATE		L	GROUP	
					6/17/04			
		.,	U.S. P.	ATENT D	OCUMENTS			
17								Filing Date
Examiner Initials		Patent Issue Date Number		Name		Class	Subclass	Appropriate
	1	6,034,093	3/7/00	Ewing et	al.			
	2	2002/183324	12/5/03	Jacobson	et al.			
	3	6,348,600	2/19/02	Ono et a				
				ontinue on				
			FOREIG	N PATEN'	T DOCUMENTS			
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No
	4	03/053925	7/3/03	PCT				
	5	03/043981	5/30/03	PCT				
	6	2004/026826	4/1/04	PCT				
	7	2002/002519	1/10/02	PCT				
	8	92/10476	6/25/92	PCT				
	9	97/43257	11/20/97	PCT				
	10	2002/080853	10/17/02	PCT				<u> </u>
					//www.			
	No.		l V			W.	(A)	
				<u></u>				
				ontinue on				
	<u>O</u>	THER DOCUMI	ENTS (Includir	ng Author	, Title, Journal-Dat	e, Page Ni	umber, Etc.)	
		-						
	-							
	ļ							4
	-	-						
	-							
		10						
	+							
	+							
	+	 						
	+					, , , , , , , , , , , , , , , , , , , ,		
			(Continue on	page			
EXAMINI	ER			- CIIIII OII	r-6-	DATE	CONSIDEREI)
22111111111								
EXAMINI	ER: In	itial if citation co	nsidered, wheth	er or not c	itation is in conform	ance with	MPEP § 609; [Draw line
					nclude copy of this f			
applicant.								